Latest News
J&J Q1: Carvykti sales surge amid continued M&A momentum
J&J Q1: Carvykti sales surge amid continued M&A momentum
With a roughly flat quarter in sales revenue, J&J said it will continue to expand capacity and cites Carvykti as a key driver for growth in 2024.
Deal-Making
.jpg?width=700&auto=webp&quality=80&disable=upscale)
Ferring Pharmaceuticals has picked CDMO SK pharmateco to commercially produce Adstiladrin, a bladder cancer gene therapy treatment.
Cellares will allocate multiple Cell Shuttles and its Cell Q systems across its facilities worldwide for Bristol Myers Squibb to produce CAR-T therapies clinically and commercially.
Facilities & Capacity
Eli Lilly will acquire Nexus Pharmaceuticals’ Pleasant Prairie, Wisconsin facility to produce injectable medicines.
CDMO Kincell Bio will support Imugene’s allogeneic CAR-T candidate Azer-cel after acquiring its North Carolina facility for up to $6 million.
Global Markets
.jpg?width=700&auto=webp&quality=80&disable=upscale)
Sartorius has closed its first quarter positively “in line” with expectations but highlights China as a continued market weakness.
Regeneron has joined its fellow pharma players in the venture investing space by committing up to $500 million over five years across the healthcare industry.
Regulations
CDMO AGC Bio will supply lentiviral vectors for Orchard Therapeutics’ metachromatic leukodystrophy (MLD) gene therapy, approved in the US this week.
Global biopharma lobbying organization BIO has forced WuXi AppTec to leave the group due to pressure from the US Congress.
Therapeutic Class
With a roughly flat quarter in sales revenue, J&J said it will continue to expand capacity and cites Carvykti as a key driver for growth in 2024.
Africa Centres for Disease Controls (CDC) has accused Moderna of abandoning its commitment to building vaccine manufacturing capabilities in Africa after pausing plans for a plant in Kenya.
Upstream & Downstream Processing
Nigel Titchener-Hooker, professor and dean of engineering at University College London, guided delegates at BioProcess International Europe in Vienna, Austria, on a tour through drug-development history.
The growing popularity of digital twins is transforming process intensification in the biopharmaceutical industry.